A research team led by Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, published a comprehensive review on Apr. 10 that examines the role of extracellular vesicle-associated RNAs (EV-RNAs) in the development and treatment of inflammatory bowel disease (IBD). The review, released in ExRNA, highlights how EV-RNAs could serve as non-invasive biomarkers for early IBD detection and monitoring, while also offering promise as targets for future therapies.
IBD is a chronic inflammatory condition affecting the gastrointestinal tract and has become an increasing public health concern worldwide. Millions suffer from its symptoms, including abdominal pain and diarrhea, which often disrupt daily life. Traditional diagnostic methods are invasive and current treatments can cause side effects or lose effectiveness over time. The need for more accurate diagnostic tools and safer therapies remains urgent.
The research team, led by Professor Xiyang Wei from the Zhejiang Key Laboratory of Multi-omics Precision Diagnosis and Treatment of Liver Diseases at Sir Run-Run Shaw Hospital in cooperation with Zhejiang Chinese Medical University researchers, summarized findings from hundreds of recent studies to show how EV-RNAs regulate key processes related to IBD. Their summary indicates that pathogenic EV-RNAs can worsen inflammation and damage intestinal barriers, while beneficial ones may help repair tissue and restore balance.
One notable finding is that gut-derived EV-RNAs may contribute to complications outside the intestine by traveling through the bloodstream to organs like the liver or heart. This mechanism could explain why some IBD patients experience extraintestinal issues such as liver injury or cardiac dysfunction.
The review points out that specific signatures found in plasma or saliva—such as elevated long non-coding RNA H19—can distinguish active IBD with high accuracy using non-invasive tests. It also discusses promising preclinical results for therapies based on mesenchymal stem cell-derived EVs or plant-based sources like bovine colostrum or Coptis chinensis extract.
Despite these advances, challenges remain before clinical adoption can occur. The lack of standardized protocols for isolating EVs and detecting their RNA content leads to inconsistent results across laboratories; large-scale clinical trials are still needed; regulatory pathways must be clarified before new treatments reach patients.
"For millions of IBD patients, this field is developing rapidly, and EV-RNAs are at the forefront of this progress," Professor Wei said. "Our review integrates all the latest evidence to show that these molecules are not just passive bystanders in the disease, but core regulators that can be targeted for both diagnosis and treatment. We hope this work will guide future research, accelerate the translation of these discoveries from the laboratory to the clinic, and ultimately bring more effective and personalized treatment to IBD patients around the world."
